CC-1065 AND THE DUOCARMYCINS - UNRAVELING THE KEYS TO A NEW CLASS OF NATURALLY DERIVED DNA ALKYLATING-AGENTS

被引:227
作者
BOGER, DL
JOHNSON, DS
机构
[1] Department of Chemistry, Scripps Research Institute, San Diego, CA 92037
关键词
D O I
10.1073/pnas.92.9.3642
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Key studies defining the DNA alkylation properties and selectivity of a new class of exceptionally potent, naturally occurring antitumor antibiotics including CC-1065, duocarmycin A, and duocarmycin SA are reviewed, Recent studies conducted with synthetic agents containing deep-seated structural changes and the unnatural enantiomers of the natural products and related analogs have defined the structural basis for the sequence-selective alkylation of duplex DNA and fundamental relationships between chemical structure, functional reactivity, and biological properties. The agents undergo a reversible, stereoelectronically controlled adenine-N3 addition to the least substituted carbon of the activated cyclopropane within selected AT-rich sites. The preferential AT-rich noncovalent binding selectivity of the agents within the narrower, deeper AT-rich minor groove and the steric accessibility to the alkylation site that accompanies deep AT-rich minor groove penetration control the sequence-selective DNA alkylation reaction and stabilize the resulting adduct, For the agents that possess sufficient reactivity to alkylate DNA, a direct relationship between chemical or functional stability and biological potency has been defined.
引用
收藏
页码:3642 / 3649
页数:8
相关论文
共 97 条
  • [1] Pullman B., Jortner J., Molecular Basis of Specificity in Nucleic Acid-Drug Interactions, (1990)
  • [2] Propst C.L., Perun T.J., Nucleic Acid Targeted Drug Design, (1992)
  • [3] Neidle S., Waring M., Molecular Aspects of Anticancer Drug-DNA Interactions, 1, (1993)
  • [4] Neidle S., Waring M., Molecular Aspects of Anticancer Drug-DNA Interactions, 2, (1994)
  • [5] Maxam A.M., Gilbert W., Proc. Natl. Acad. Sci. USA, 74, pp. 560-564, (1977)
  • [6] Maxam A.M., Gilbert W., Methods Enzymol., 65, pp. 499-560, (1980)
  • [7] Sanger F., Nicklen S., Coulson A.R., Proc. Natl. Acad. Sci. USA, 74, pp. 5463-5467, (1977)
  • [8] Ambrose B.J.B., Pless R.C., Methods Enzymol., 152, pp. 522-538, (1987)
  • [9] Barnes W.M., Methods Enzymol., 152, pp. 538-556, (1987)
  • [10] Dabrowiak J.C., Stankus A.A., Goodisman J., Nucleic Acid Targeted Drug Design, pp. 93-149, (1992)